Literature DB >> 16796587

A new de novo Notch3 mutation causing CADASIL.

E Coto1, M Menéndez, R Navarro, M García-Castro, V Alvarez.   

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is one of the most common hereditary forms of stroke, and migraine with aura, mood disorders, or dementia, are also frequently found in these patients. Missense mutations in the Notch3 gene that create or destroy cysteine residues, have been found in most cases with a family history of the disease, although a few sporadic cases harbouring Notch3 mutations have also been described. Here, we describe a 44-year-old patient with clinical features of CADASIL who was a carrier of a new Notch3 mutation: cys128-->gly. Both parents were alive and healthy, and negative for the mutation. This case illustrates the interest of analysing the Notch3 gene in cases with clinical features of CADASIL, even in the absence of a family history of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796587     DOI: 10.1111/j.1468-1331.2006.01337.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  16 in total

Review 1.  Genetic animal models of cerebral vasculopathies.

Authors:  Jeong Hyun Lee; Brian J Bacskai; Cenk Ayata
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 2.  Notch and disease: a growing field.

Authors:  Angeliki Louvi; Spyros Artavanis-Tsakonas
Journal:  Semin Cell Dev Biol       Date:  2012-02-20       Impact factor: 7.727

Review 3.  Imaging characteristics of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL).

Authors:  Dragan Stojanov; Slobodan Vojinovic; Aleksandra Aracki-Trenkic; Aleksandar Tasic; Daniela Benedeto-Stojanov; Srdjan Ljubisavljevic; Sasa Vujnovic
Journal:  Bosn J Basic Med Sci       Date:  2015-02-09       Impact factor: 3.363

Review 4.  Cerebrovascular disorders associated with genetic lesions.

Authors:  Philipp Karschnia; Sayoko Nishimura; Angeliki Louvi
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

5.  A Next-Generation Sequencing of the NOTCH3 and HTRA1 Genes in CADASIL Patients.

Authors:  Angela Fernández; Juan Gómez; Belén Alonso; Sara Iglesias; Eliecer Coto
Journal:  J Mol Neurosci       Date:  2015-05-01       Impact factor: 3.444

Review 6.  Stroke-related translational research.

Authors:  Louis R Caplan; Juan Arenillas; Steven C Cramer; Anne Joutel; Eng H Lo; James Meschia; Sean Savitz; Elizabeth Tournier-Lasserve
Journal:  Arch Neurol       Date:  2011-05-09

Review 7.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Authors:  Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri
Journal:  Stroke       Date:  2011-07-21       Impact factor: 7.914

8.  Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: a genetic cause of cerebral small vessel disease.

Authors:  Jay Chol Choi
Journal:  J Clin Neurol       Date:  2010-03-26       Impact factor: 3.077

9.  De novo mutation in the NOTCH3 gene causing CADASIL.

Authors:  Dragan Stojanov; Danijela Grozdanović; Sladjana Petrović; Daniela Benedeto-Stojanov; Ivan Stefanović; Nebojša Stojanović; Dušica N Ilić
Journal:  Bosn J Basic Med Sci       Date:  2014-02       Impact factor: 3.363

Review 10.  Diagnostic criteria for CADASIL in the International Classification of Headache Disorders (ICHD-II): are they appropriate?

Authors:  Simona Sacco; Diana Degan; Antonio Carolei
Journal:  J Headache Pain       Date:  2010-03-12       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.